Aurobindo Pharma submits ANDA for Empagliflozin and Metformin Hydrochloride
Aurobindo Pharma has submitted an Abbreviated New Drug Application (ANDA) for Empagliflozin and Metformin Hydrochloride.
Therapeutic Area
Therapeutic area intelligence for SGLT2 Inhibitor and Biguanide with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.